 Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 3 | 5 | | 2007 | 4 | 1 | 5 | | 2008 | 3 | 3 | 6 | | 2009 | 6 | 2 | 8 | | 2010 | 3 | 4 | 7 | | 2011 | 10 | 4 | 14 | | 2012 | 5 | 3 | 8 | | 2013 | 7 | 3 | 10 | | 2014 | 7 | 2 | 9 | | 2015 | 6 | 1 | 7 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 5 | 6 | | 2018 | 2 | 3 | 5 | | 2019 | 4 | 0 | 4 | | 2020 | 1 | 1 | 2 | | 2021 | 3 | 3 | 6 | | 2022 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022 10 01; 32(5):324-333.
-
Shim SH, Tufa D, Woods R, George TD, Shank T, Yingst A, Lake J, Cobb L, Jones D, Jones K, Verneris MR. SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium. Stem Cells Transl Med. 2022 05 27; 11(5):513-526.
-
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Mol Cancer Ther. 2022 03 01; 21(3):397-406.
-
Çakir I, Hadley CK, Pan PL, Bagchi RA, Ghamari-Langroudi M, Porter DT, Wang Q, Litt MJ, Jana S, Hagen S, Lee P, White A, Lin JD, McKinsey TA, Cone RD. Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nat Metab. 2022 01; 4(1):44-59.
-
Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, Yuno A, Greer J, Smith BD, Pratz KW, Levis MJ, Gore SD, Ghosh N, Dezern A, Blackford AL, Baer MR, Gore L, Piekarz R, Trepel JB, Karp JE. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk Res. 2021 11; 110:106707.
-
Kibbie JJ, Dillon SM, Thompson TA, Purba CM, McCarter MD, Wilson CC. Butyrate directly decreases human gut lamina propria CD4 T cell function through histone deacetylase (HDAC) inhibition and GPR43 signaling. Immunobiology. 2021 09; 226(5):152126.
-
Zou M, Jiang D, Wu T, Zhang X, Zhao Y, Wu D, Sun W, Cui J, Moreland L, Li G. Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. Hum Mol Genet. 2021 05 28; 30(9):823-835.
-
Bertels Z, Singh H, Dripps I, Siegersma K, Tipton AF, Witkowski WD, Sheets Z, Shah P, Conway C, Mangutov E, Ao M, Petukhova V, Karumudi B, Petukhov PA, Baca SM, Rasenick MM, Pradhan AA. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition. Elife. 2021 04 15; 10.
-
Zhang H, Laux A, Stenmark KR, Hu CJ. Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension. Int J Mol Sci. 2021 Apr 08; 22(8).
-
Travers JG, Wennersten SA, Peña B, Bagchi RA, Smith HE, Hirsch RA, Vanderlinden LA, Lin YH, Dobrinskikh E, Demos-Davies KM, Cavasin MA, Mestroni L, Steinkühler C, Lin CY, Houser SR, Woulfe KC, Lam MPY, McKinsey TA. HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. Circulation. 2021 05 11; 143(19):1874-1890.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|